IGF2BP3 and breast carcinoma: Targeting regulators such as METTL3, METTL14, IGF2BP3, or YTHDF1 can alleviate T-cell suppression in melanoma, colorectal cancer, non-small cell lung cancer (NSCLC), and breast cancer.